𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Meta-analysis: Reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C

✍ Scribed by Yasuhiro Miyake; Yoshiaki Iwasaki; Kazuhide Yamamoto

Publisher
John Wiley and Sons
Year
2009
Tongue
French
Weight
252 KB
Volume
127
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Interferon treatment for chronic hepatitis C reduces the incidence of hepatocellular carcinoma (HCC) in sustained responders. However, estimation of the effect of interferon treatment on HCC development in nonresponders is yet to be fully implemented. We conducted a meta‐analysis of 3 randomized controlled trials and 6 prospective cohort studies, including 3,246 patients (1,922 patients received interferon treatment) to estimate the effect of single‐course interferon treatment on HCC development in patients with chronic hepatitis C. Single‐course interferon treatment prevented HCC development (RR 0.45; 95% CI 0.31–0.65). This preventive effect was shown even in nonresponders (RR 0.48; 95% CI 0.25–0.90). By subgroup analyses, single‐course interferon treatment reduced HCC incidence in cirrhotic patients (RR 0.49; 95% CI 0.29–0.84), patients with annual HCC incidence less than 3% in control group (RR 0.42; 95% CI 0.26–0.66) and patients with annual HCC incidence of 3% or more in control group (RR 0.46; 95% CI 0.26–0.83). Furthermore, HCC incidence was reduced in 3 studies with follow‐up period less than 5 years (RR 0.38; 95% CI 0.21–0.66) and in 6 studies with follow‐up period of 5 years or more (RR 0.46; 95% CI 0.28–0.76). In conclusion, single‐course interferon treatment was shown to prevent HCC development in chronic hepatitis C, even in nonresponders. This preventive effect may be speculated to be due to anti‐inflammatory effect on persistent necro‐inflammation and blocking progression of fibrosis in liver. Even if sustained virological response is not achieved, interferon may be worth administering in order to reduce HCC incidence in patients with chronic hepatitis C.

📜 SIMILAR VOLUMES

Varying incidence of cirrhosis and hepat
Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy
✍ Michiko Shindo; Arai Ken; Tadao Okuno 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 3 views

## BACKGROUND. To determine whether interferon (IFN) therapy can reduce incidence of the development of cirrhosis and hepatocellular carcinoma equally in patients with chronic hepatitis C virus (HCV) who responded differently to therapy, a retrospective analysis of 250 patients treated with IFN wa

Characteristics of patients with chronic
Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy
✍ Akiko Makiyama; Yoshito Itoh; Akinori Kasahara; Yasuharu Imai; Sumio Kawata; Ken 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 3 views

## Abstract ## BACKGROUND The objective of the current study was to determine the characteristic features of sustained responders who develop hepatocellular carcinoma after treatment with interferon for chronic hepatitis C. ## METHODS This study included 3626 patients with chronic hepatitis C wh

The effect of retreatment with interfero
The effect of retreatment with interferon-α on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C
✍ Hidenori Toyoda; Takashi Kumada; Satoshi Nakano; Isao Takeda; Keiichi Sugiyama; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

BACKGROUND. Interferon (IFN) has been reported to have beneficial long term effects that reduce the occurrence of hepatocellular carcinoma (HCC), even in patients who do not have complete responses to IFN. The authors evaluated the effect of retreatment with IFN-␣ on the long term prognoses of those

Pegylated interferon monotherapy of chro
Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials
✍ Fabrizio Fabrizi; Vivek Dixit; Piergiorgio Messa; Paul Martin 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

## Abstract The efficacy and safety of pegylated interferon monotherapy in patients with chronic renal failure and chronic hepatitis C remains unclear, although a number of small clinical trials have been published addressing this issue. A systematic review of the literature with a meta‐analysis of